Immunic: Potent Under-The-Radar MS Lineup Set For A Rerating (NASDAQ:IMUX)
· seekingalpha.com
Immunic (IMUX) advances oral IMU-838 in late-stage MS trials, targeting a $22B market by 2026.
This is my first article on Immunic ( IMUX ) a late clinical stage German-founded biotech that I have been following for a year or more. My interest in this com...